ResearcherNanjing University of Chinese MedicineActive in the last 2 years
Juan Du
Matched on ORCID iD 0000-0003-4701-3573; OpenAlex author ID A5088127595. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 0, last author 5)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 16
2022: 2 papers · 2023: 1 paper · 2024: none · 2025: 2 papers
Papers 5
- Construction of feature selection and efficacy prediction model for transformation therapy of locally advanced pancreatic cancer based on CT, 18F-FDG PET/CT, D… Last author DOI 10.1186/s12935-025-03639-8↗
- Radiotherapy and immune microenvironment crosstalk in pancreatic cancer: a comprehensive review of current insights and future directions. Last author DOI 10.3389/fimmu.2025.1619946↗
- Making "cold" tumors "hot"- radiotherapy remodels the tumor immune microenvironment of pancreatic cancer to benefit from immunotherapy: a case report. Last author DOI 10.3389/fimmu.2023.1277810↗
- Study protocol for a prospective, open-label, single-arm, phase II study on the combination of tislelizumab, nab-paclitaxel, gemcitabine, and concurrent radiot… Last author DOI 10.3389/fonc.2022.879661↗
- Case Report: Pathologic Complete Response to Induction Therapy in a Patient With Potentially Resectable Pancreatic Cancer. Last author DOI 10.3389/fonc.2022.898119↗
Closest collaborators
The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Baorui Liu · 4 shared papers, 2022–2025 · strength 0.68
- Paper Construction of feature selection and efficacy prediction model for transformation therapy of locally advanced pancreat… DOI 10.1186/s12935-025-03639-8↗
- Paper Making "cold" tumors "hot"- radiotherapy remodels the tumor immune microenvironment of pancreatic cancer to benefit fro… DOI 10.3389/fimmu.2023.1277810↗
- Paper Study protocol for a prospective, open-label, single-arm, phase II study on the combination of tislelizumab, nab-paclit… DOI 10.3389/fonc.2022.879661↗
- Liang Qi · 2 shared papers, 2023–2025 · strength 0.43
- Paper Construction of feature selection and efficacy prediction model for transformation therapy of locally advanced pancreat… DOI 10.1186/s12935-025-03639-8↗
- Paper Making "cold" tumors "hot"- radiotherapy remodels the tumor immune microenvironment of pancreatic cancer to benefit fro… DOI 10.3389/fimmu.2023.1277810↗
- Yudong Qiu · 1 shared paper, 2025 · strength 0.37
- Yucheng Xu · 1 shared paper, 2025 · strength 0.37
- Xiang Li · 1 shared paper, 2025 · strength 0.27
- Linxi Zhu · 2 shared papers, 2022 · strength 0.25
- Paper Study protocol for a prospective, open-label, single-arm, phase II study on the combination of tislelizumab, nab-paclit… DOI 10.3389/fonc.2022.879661↗
- Paper Case Report: Pathologic Complete Response to Induction Therapy in a Patient With Potentially Resectable Pancreatic Canc… DOI 10.3389/fonc.2022.898119↗
- Changchang Lu · 2 shared papers, 2022 · strength 0.25
- Paper Study protocol for a prospective, open-label, single-arm, phase II study on the combination of tislelizumab, nab-paclit… DOI 10.3389/fonc.2022.879661↗
- Paper Case Report: Pathologic Complete Response to Induction Therapy in a Patient With Potentially Resectable Pancreatic Canc… DOI 10.3389/fonc.2022.898119↗
- Lei Wang · 2 shared papers, 2022 · strength 0.25
- Paper Study protocol for a prospective, open-label, single-arm, phase II study on the combination of tislelizumab, nab-paclit… DOI 10.3389/fonc.2022.879661↗
- Paper Case Report: Pathologic Complete Response to Induction Therapy in a Patient With Potentially Resectable Pancreatic Canc… DOI 10.3389/fonc.2022.898119↗
- Yudong Qiu · 2 shared papers, 2022 · strength 0.25
- Paper Study protocol for a prospective, open-label, single-arm, phase II study on the combination of tislelizumab, nab-paclit… DOI 10.3389/fonc.2022.879661↗
- Paper Case Report: Pathologic Complete Response to Induction Therapy in a Patient With Potentially Resectable Pancreatic Canc… DOI 10.3389/fonc.2022.898119↗
- Xin Qiu · 2 shared papers, 2022 · strength 0.25
- Paper Study protocol for a prospective, open-label, single-arm, phase II study on the combination of tislelizumab, nab-paclit… DOI 10.3389/fonc.2022.879661↗
- Paper Case Report: Pathologic Complete Response to Induction Therapy in a Patient With Potentially Resectable Pancreatic Canc… DOI 10.3389/fonc.2022.898119↗
- Qi Li · 2 shared papers, 2022 · strength 0.25
- Paper Study protocol for a prospective, open-label, single-arm, phase II study on the combination of tislelizumab, nab-paclit… DOI 10.3389/fonc.2022.879661↗
- Paper Case Report: Pathologic Complete Response to Induction Therapy in a Patient With Potentially Resectable Pancreatic Canc… DOI 10.3389/fonc.2022.898119↗
- Jun Chen · 2 shared papers, 2022 · strength 0.25
- Paper Study protocol for a prospective, open-label, single-arm, phase II study on the combination of tislelizumab, nab-paclit… DOI 10.3389/fonc.2022.879661↗
- Paper Case Report: Pathologic Complete Response to Induction Therapy in a Patient With Potentially Resectable Pancreatic Canc… DOI 10.3389/fonc.2022.898119↗
- Huizi Sha · 1 shared paper, 2023 · strength 0.17
- Fan Tong · 1 shared paper, 2023 · strength 0.17
- Ju Dong Yang · 1 shared paper, 2022 · strength 0.12
- Hao Cheng · 1 shared paper, 2022 · strength 0.12
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.